Cogent Biosciences said its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Detailed price information for Verona Pharma Plc ADR (VRNA-Q) from The Globe and Mail including charting and trades.

Fintel reports that on June 17, 2025, Wells Fargo downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 0.45% Downside ...

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment ...

Fintel reports that on June 4, 2025, Citigroup upgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Sell to Neutral. Analyst Price Forecast Suggests 0.05% Upside As of June 2, 2025 ...

Blueprint Medicines, known for its focus on systemic mastocytosis (SM)—a rare disorder characterized by an abnormal accumulation of mast cells—and other KIT-related conditions, has agreed to ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology ...

Blueprint Medicines Corporation (NASDAQ:BPMC), a commercial-stage biotechnology company specializing in precision therapies for cancer and rare diseases, has been making significant strides in the ...